Management of Crohn's disease in adults

@article{Hanauer2001ManagementOC,
  title={Management of Crohn's disease in adults},
  author={Stephen Hanauer and William J. Sandborn},
  journal={American Journal of Gastroenterology},
  year={2001},
  volume={96},
  pages={635-643}
}
Guidelines for clinical practice are intended to suggest preferable approaches to particular medical problems as established by interpretation and collation of scientifically valid research, derived from extensive review of published literature. When data are not available that will withstand objective scrutiny, a recommendation may be made based on a consensus of experts. Guidelines are intended to apply to the clinical situation for all physicians without regard to specialty. Guidelines are… 
Management of Crohn's Disease in Adults
TLDR
These guidelines are developed under the auspices of the American College of Gastroenterology and its Practice Parameters Committee and may be updated with pertinent scientific developments at a later time.
ACG Clinical Guideline: Management of Crohn’s Disease in Adults
TLDR
This guideline is intended to be flexible, not necessarily indicating the only acceptable approach, and should be distinguished from standards of care that are inflexible and rarely violated.
European evidence-based consensus on the diagnosis and management of Crohn’s disease
TLDR
The aim of the consensus was not to “supersede guidelines of different countries”, but to promote a European perspective on the management of Crohn's disease under the auspices of the European Crohn’s and Colitis Organization (ECCO).
A practical, evidence-based guide to the use of adalimumab in Crohn’s disease
TLDR
A practical, evidence-based guide to help clinicians optimize the use of adalimumab in patients with Crohn’s disease and suggests that patients experiencing attenuation of response or inflammatory-mediated symptoms during maintenance therapy may benefit from dosage intensification to weekly ad alimumab.
Established Management Paradigms in IBD: Treatment Targets and Therapeutic Tools
TLDR
This study focuses and expands on areas that are not clearly delineated in current guidelines, including the role of prognostication, to determine patient treatment paradigms and the opportunity for a more individualized approach that can inform the selection of immunosuppressant or biologic therapy.
Converging goals of treatment of inflammatory bowel disease from clinical trials and practice.
TLDR
A combination of end points, comprising patient-reported outcomes and objective evaluation of inflammation by endoscopy, offers a clinically meaningful and scientifically valid alternative to existing composite indices.
Infliximab for the Treatment of Crohn ’ s Disease : A Systematic Review and Cost-Utility Analysis Technology Report
TLDR
Unpublished efficacy and effectiveness data were sought from pharmaceutical companies involved in the production and distribution of infliximab and the websites of relevant international government agencies were searched.
Management of active Crohn disease.
TLDR
Immunomodulators and biologics are now the preferred treatment options for Crohn disease, particularly anti-tumor necrosis factor.
Self-management for people with inflammatory bowel disease.
TLDR
A framework for the use of self-management in the IBD population is provided, with emphasis on the concept of a patient passport, and theUse of e-mail, supported by an e-mails contract, as proposed by the Canadian Medical Protective Association.
...
...

References

SHOWING 1-10 OF 179 REFERENCES
Corticosteroids for maintenance of remission in Crohn's disease.
TLDR
The use of conventional systemic corticosteroids in patients with clinically quiescent Crohn's disease does not appear to reduce the risk of relapse over a 24 month period of follow-up.
Practice guidelines for inflammatory bowel disease: an instrument for assessment.
TLDR
The hypothesis is presented that practice guidelines that provide specific objectives for assessment and intervention in inflammatory bowel disease can be used to measure practice variation and to assess the benefits of practice guidelines.
Corticosteroids for maintaining remission of Crohn's disease.
TLDR
The use of conventional systemic corticosteroids in patients with clinically quiescent Crohn's disease does not appear to reduce the risk of relapse over a 24 month period of follow-up.
Differentiation between Crohn's disease and ulcerative colitis.
Low symptomatic load in Crohn's disease with surgery and medicine as complementary treatments.
TLDR
The great majority of patients with Crohn's disease are able to live in remission or experience only mild symptoms, as reflected in a cross-sectional study of the symptom index, physicians' assessment, and the patients' perception of health.
Standards for Approval of New Drugs for IBD
  • S. Fredd
  • Medicine
    Inflammatory bowel diseases
  • 1995
The following article by Dr. Stephen Fredd, Director of the Division of Gastrointestinal and Coagulation Drug Products at the Food and Drug Administration (FDA), outlines the process of drug approval
Risk Factors and Distinguishing Features of Cancer in IBD
  • A. Ekbom
  • Medicine
    Inflammatory bowel diseases
  • 1998
TLDR
There is aneed for a well-defined study base when assessing the risk for cancer, and this is the need for a control population for this very clinical problem.
Clinical economics review: medical management of inflammatory bowel disease
Inflammatory bowel diseases, although they are uncommon and rarely fatal, typically present during the period of economically productive adult life. Patients may require extensive therapeutic
Anti-tuberculous therapy for maintaining remission of Crohn's disease.
TLDR
Anti-tuberculous therapy may be effective in maintaining remission in patients with Crohn's disease when remission has been induced with corticosteroids combined with anti-tubculous Therapy.
...
...